Janux Therapeutics, Inc. Earnings Per Share (Basic)
Janux Therapeutics, Inc. (JANX) reported Earnings Per Share (Basic) of -$0.35 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-06
- Janux Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.35.
- Janux Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.39.
- Janux Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.51.
- Janux Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.39.
- Janux Therapeutics, Inc. earnings per share, basic for fiscal 2025 was -$1.83.
- Janux Therapeutics, Inc. earnings per share, basic for fiscal 2024 was -$1.28.
- Janux Therapeutics, Inc. earnings per share, basic for fiscal 2023 was -$1.32.
- Janux Therapeutics, Inc. earnings per share, basic for fiscal 2022 was -$1.52.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.35 10-Q · filed 2026-08-06 | -$0.74 10-Q · filed 2026-08-06 | -$1.25 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.64 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2026-03-31 | -$0.39 10-Q · filed 2026-05-07 | -$0.90 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$1.29 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$1.84 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-12-31 | -$0.51 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$0.91 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$1.45 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.83 10-K · filed 2026-02-26 |
| 2025-09-30 | -$0.39 10-Q · filed 2025-11-06 | -$0.94 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.32 10-Q · filed 2025-11-06 | -$1.68 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-06-30 | -$0.55 10-Q · filed 2026-08-06 | -$0.93 10-Q · filed 2026-08-06 | -$1.29 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$1.80 derived: net income ÷ weighted average shares · filed 2026-08-06 |
| 2025-03-31 | -$0.38 10-Q · filed 2026-05-07 | -$0.74 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$1.24 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$1.37 derived: net income ÷ weighted average shares · filed 2026-05-07 |
| 2024-12-31 | -$0.36 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$0.87 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$0.98 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$1.28 10-K · filed 2026-02-26 |
| 2024-09-30 | -$0.51 10-Q · filed 2025-11-06 | -$0.62 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$0.93 10-Q · filed 2025-11-06 | -$1.18 derived: net income ÷ weighted average shares · filed 2026-02-26 |
| 2024-06-30 | -$0.11 10-Q · filed 2025-08-07 | -$0.40 10-Q · filed 2025-08-07 | -$0.65 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$0.90 derived: net income ÷ weighted average shares · filed 2026-02-26 |
| 2024-03-31 | -$0.30 10-Q · filed 2025-05-08 | -$0.55 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$0.81 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$1.21 derived: net income ÷ weighted average shares · filed 2026-02-26 |
| 2023-12-31 | -$0.25 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$0.50 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$0.91 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$1.32 10-K · filed 2026-02-26 |
| 2023-09-30 | -$0.25 10-Q · filed 2024-11-06 | -$0.66 derived: net income ÷ weighted average shares · filed 2024-11-06 | -$1.08 10-Q · filed 2024-11-06 | -$1.47 derived: net income ÷ weighted average shares · filed 2025-02-27 |
| 2023-06-30 | -$0.42 10-Q · filed 2024-08-07 | -$0.84 10-Q · filed 2024-08-07 | -$1.22 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$1.63 derived: net income ÷ weighted average shares · filed 2025-02-27 |
| 2023-03-31 | -$0.42 10-Q · filed 2024-05-08 | -$0.80 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$1.21 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$1.61 derived: net income ÷ weighted average shares · filed 2025-02-27 |
| 2022-12-31 | -$0.39 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$0.79 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$1.20 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$1.52 10-K · filed 2025-02-27 |
| 2022-09-30 | -$0.40 10-Q · filed 2023-11-07 | -$0.81 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$1.13 10-Q · filed 2023-11-07 | -$1.46 derived: net income ÷ weighted average shares · filed 2023-11-07 |
| 2022-06-30 | -$0.41 10-Q · filed 2023-08-08 | -$0.73 10-Q · filed 2023-08-08 | -$1.06 derived: net income ÷ weighted average shares · filed 2023-08-08 | -$1.32 derived: net income ÷ weighted average shares · filed 2023-08-08 |
| 2022-03-31 | -$0.32 10-Q · filed 2023-05-09 | -$0.65 derived: net income ÷ weighted average shares · filed 2023-05-09 | -$0.91 derived: net income ÷ weighted average shares · filed 2023-05-09 | -$1.31 derived: net income ÷ weighted average shares · filed 2023-05-09 |
| 2021-12-31 | -$0.32 derived: net income ÷ weighted average shares · filed 2023-03-10 | -$0.59 derived: net income ÷ weighted average shares · filed 2023-03-10 | -$0.98 derived: net income ÷ weighted average shares · filed 2023-03-10 | -$1.39 10-K · filed 2023-03-10 |
| 2021-09-30 | -$0.26 10-Q · filed 2022-11-10 | -$0.66 derived: net income ÷ weighted average shares · filed 2022-11-10 | -$1.10 10-Q · filed 2022-11-10 | -$1.62 derived: net income ÷ weighted average shares · filed 2022-11-10 |
| 2021-06-30 | -$0.62 10-Q · filed 2022-08-09 | -$1.52 10-Q · filed 2022-08-09 | -$2.90 derived: net income ÷ weighted average shares · filed 2022-08-09 | -$4.26 derived: net income ÷ weighted average shares · filed 2022-08-09 |
| 2021-03-31 | -$7.51 derived: net income ÷ weighted average shares · filed 2022-05-10 | -$16.66 derived: net income ÷ weighted average shares · filed 2022-05-10 | -$23.07 derived: net income ÷ weighted average shares · filed 2022-05-10 | -$32.90 derived: net income ÷ weighted average shares · filed 2022-05-10 |
| 2020-12-31 | -$9.82 derived: net income ÷ weighted average shares · filed 2022-03-18 | -$15.69 derived: net income ÷ weighted average shares · filed 2022-03-18 | -$25.72 derived: net income ÷ weighted average shares · filed 2022-03-18 | -$29.03 derived: net income ÷ weighted average shares · filed 2022-03-18 |
| 2020-09-30 | -$6.20 derived: net income ÷ weighted average shares · filed 2021-11-09 | -$16.23 derived: net income ÷ weighted average shares · filed 2021-11-09 | -$20.08 derived: net income ÷ weighted average shares · filed 2021-11-09 | |
| 2020-06-30 | -$9.63 derived: net income ÷ weighted average shares · filed 2021-08-10 | -$13.73 derived: net income ÷ weighted average shares · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |